Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease.
Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia.
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.
Chronic myelogenous leukemia. Preface.
Systemic mastocytosis: current classification and novel therapeutic options.
Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer?
Patient Management Issues with Imatinib Mesylate in CML and Other Hematologic Malignancies
Fatal hepatic necrosis following imatinib mesylate therapy.
Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.
How to treat chronic myeloid leukemia (CML) in older adults.